# Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

> **NCT02298348** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **New Approaches to Neuroblastoma Therapy Consortium** · enrollment: 18 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Cyclophosphamide
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT02298348
- **Lead sponsor:** New Approaches to Neuroblastoma Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10-08
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02298348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02298348, "Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02298348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*